Icosavax Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019
Cash & Equivalents	59.91	280.72	15.5	23.08
Short-Term Investments	159.46	0	0	0
Cash & Cash Equivalents	219.37	280.72	15.5	23.08
Cash Growth	-21.86%	1711.36%	-32.85%	-
Other Current Assets	4.55	5.83	0.66	0.21
Total Current Assets	223.91	286.55	16.16	23.29
Property, Plant & Equipment	14.76	1.08	0.01	0
Total Long-Term Assets	14.76	1.08	0.01	0
Total Assets	238.68	287.63	16.17	23.29
Accounts Payable	2.89	3.9	1.92	0.8
Deferred Revenue	0	0.58	2.38	0
Current Debt	2.14	0	0	0
Other Current Liabilities	8.76	4.76	1.53	0.42
Total Current Liabilities	13.79	9.24	5.83	1.22
Long-Term Debt	6.66	0	4.95	0
Other Long-Term Liabilities	0.07	0.17	2.03	0.25
Total Long-Term Liabilities	6.73	0.17	6.98	0.25
Total Liabilities	20.52	9.41	12.81	1.47
Total Debt	8.8	0	4.95	0
Common Stock	404.39	372.29	0.4	0
Retained Earnings	-185.83	-94.07	-27.1	-8.24
Comprehensive Income	-0.4	0	0	0
Shareholders' Equity	218.16	278.22	-26.7	-8.24
Net Cash / Debt	210.57	280.72	10.55	23.08
Net Cash / Debt Growth	-24.99%	2560.64%	-54.28%	-
Net Cash Per Share	5.30	15.63	4.70	3.50
Working Capital	210.13	277.32	10.33	22.07
Book Value Per Share	5.49	15.49	-11.89	-1.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).